SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 10, 2007
ELI LILLY AND COMPANY
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Indiana
(State or Other Jurisdiction
of Incorporation)
|
|
001-06351
(Commission
File Number)
|
|
35-0470950
(I.R.S. Employer
Identification No.) |
| |
|
|
|
|
Lilly Corporate Center
Indianapolis, Indiana
(Address of Principal
Executive Offices)
|
|
|
|
46285
(Zip Code) |
Registrant’s telephone number, including area code: (317) 276-2000
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item 2.05 Costs Associated with Exit or Disposal Activities
and
Item 2.06 Material Impairments
On January 10, 2007, the board of directors of Eli Lilly and Company approved several strategic
changes to the company’s manufacturing operations, including decisions to stop construction of the
planned insulin manufacturing plant in Prince William County, Virginia, and to offer a voluntary
exit program for up to 250 employees at Tippecanoe Laboratories in West Lafayette, Indiana.
Construction of the Prince William County plant will stop, as the company is now able to meet
expected growth in insulin demand with existing sites and new insulin capacity that is being built
in Sesto, Italy. All of the 120 employees working at the site who wish to stay with Lilly will be
given opportunities for jobs at other company sites. Those who choose not to stay will be given a
severance package.
In response to excess capacity in Lilly’s small molecule active ingredient operations, a voluntary
exit program is being offered for up to 250 employees at Lilly’s Tippecanoe manufacturing site.
This program allows employees to voluntarily leave or retire from the company with an enhanced
severance package based on years of service. There are about 1,000 employees currently working at
the site.
The estimated restructuring and asset impairment charges for these actions will be approximately
$155 to $185 million. These charges will be split between the fourth quarter of 2006 and the first
quarter of 2007. The fourth quarter 2006 charge of approximately $90 million, or 5 cents per
share, is primarily a non-cash charge for asset impairments. The first quarter 2007 charges will
relate to severance and contract terminations, substantially all of which will be in cash.
Item 8.01 Other Events
On Thursday, January 4, 2007, the company issued a press release announcing that it had entered
into settlement agreements with several plaintiffs’ firms involved in Zyprexa® liability litigation
to resolve the vast majority of remaining product liability claims relating to the medication. At
that time, the exact number of claimants covered by this settlement could not be determined, but
was estimated to be more than 18,000. Approximately 1,200 claims that have been identified to
Lilly are not included in this settlement.
In the release, the company stated that it would record a fourth quarter 2006 charge in connection
with the settlements and estimated that the charge, which was still under review at that time,
would not exceed $500 million. The amount of the charge has now been determined to be
approximately $495 million, or $.42 per share after taxes.
2